BIOGEN IDEC TITLE OF Q1 2013 FINANCIAL RESULTS & BUSINESS UPDATE

TITLE OF PRESENTATION BIOGEN IDEC Q1 2013 FINANCIAL RESULTS & BUSINESS UPDATE

APRIL 25, 2013

Forward-Looking Statements This presentation contains forward-looking statements, including statements about potential product launches, 2013 financial guidance, growth prospects, regulatory submissions and agency actions, the anticipated financial and operational impact of our acquisition of TYSABRI rights from Elan, and the development, commercialization and therapeutic impact of new and potential treatments. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including our dependence on our three principal products, AVONEX, TYSABRI and RITUXAN, the importance of TYSABRI’s sales growth, uncertainty of success in executing our commercial launch of TECFIDERA, uncertainty of success in commercializing and developing other products, product competition, the occurrence of adverse safety events with our products, changes in the availability of reimbursement for our products, adverse market and economic conditions, our dependence on collaborations and other third parties over which we may not always have full control, problems with our manufacturing processes and our reliance on third parties, failure to comply with government regulation, our ability to protect our intellectual property rights and have sufficient rights to market our products together with the cost of doing so, the risks of doing business internationally, failure to manage our growth and execute our growth initiatives, charges and other costs relating to our properties, fluctuations in our effective tax rate, our ability to attract and retain qualified personnel, product liability claims, fluctuations in our operating results, the market, interest and credit risks associated with our portfolio of marketable securities, environmental risks, change of control provisions in our collaborations and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the SEC. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements. 2

2

BIIB Q1 2013 Earnings Call Agenda

INTRODUCTION CLAUDINE PROWSE, Ph.D., VP, Investor Relations

OVERVIEW GEORGE SCANGOS, Ph.D., Chief Executive Officer

COMMERCIAL UPDATE TONY KINGSLEY, EVP, Global Commercial Operations

R&D UPDATE DOUG WILLIAMS, Ph.D., EVP, Research & Development

FINANCIAL PERFORMANCE PAUL CLANCY, EVP, Chief Financial Officer

3

TITLE OF PRESENTATION GEORGE SCANGOS, Ph.D., CHIEF EXECUTIVE OFFICER

OVERVIEW

1.40

1.97

975

1,096

Q1 2013 Financial Performance

Non-GAAP Diluted EPS ($)* Total Revenues ($M) Product Revenues ($M)

Q1-12 Q1-13 Q1-12 Q1-13 Q1-12 Q1-13

+10% +41% +12%

1,292

1,415

*A RECONCILIATION OF OUR GAAP TO NON-GAAP RESULTS IS INCLUDED AT THE END OF THIS PRESENTATION 5

Q1 2013 Product Performance

AVONEX® ($M) TYSABRI® ($M) RITUXAN® ($M)*

401 491

261

255

Q1-12 Q1-13

US ROW

662

746

87 113

198 199

Q1-12 Q1-13

US ROW

285 265**

Q1-12 Q1-13

BIIB Revenue

286 312

*TOTAL REVENUE FROM UNCONSOLIDATED JOINT BUSINESS

** INCLUDES $42M CHARGE FOR RITUXAN ARBITRATION

+13% +9% -7%

6

Highlights

Strong Q1 2013 Financial Results Total revenues increased 10% Y/Y to

$1.4 Billion AVONEX & TYSABRI both delivered

solid revenue growth Ongoing global rollout of the AVONEX

Pen® continues to be a key driver of performance

TYSABRI utilization continues to be driven by its high efficacy profile

Benefited from low GAAP and non-GAAP tax rates of 13.2% and 14.0%, respectively

GAAP diluted EPS up 43%; non-GAAP diluted EPS rises 41%

TECFIDERA™ (Dimethyl Fumarate) Approved and Launched in the US as a First-Line Oral Treatment for Relapsing Forms of MS CHMP Issued a Positive Opinion for TECFIDERA as a First-Line Treatment for RRMS in the European Union Tecfidera Approved in Canada as First-Line Oral treatment for RRMS. New TECFIDERA US Patent Offers Protection Until 2028 and Strengthens Growing Product Patent Portfolio

European patent office determined that this patent is also allowable

Gained Full Ownership, Strategic, Commercial and Decision-Making Rights to TYSABRI® from Elan

Operational highlights Other highlights

7

A Remarkable Period for Biogen Idec

TECFIDERATM (Dimethyl Fumarate): Providing a strong oral option for MS treatment

8 8

Strong efficacy Favorable safety profile Convenience of oral administration

High physician awareness

Anticipate broad appeal to a large segment of prescribing neurologists and MS patients

*Under Active Review with EMA

Improved IP offers protection until 2028

TYSABRI Asset Purchase

BIIB purchases full ownership of important therapy with positive share and revenue growth trajectory as well as expanding margins

Enables operational simplicity that will allow for more nimble and focused execution

Immediately and sustainably accretive to earnings

Offers fair valuation with significant potential operational and tax synergies

Eliminates change of control provision

Biogen Idec Purchased Full Rights and Control of TYSABRI from Elan for Upfront Cash and Contingent Payments

9

TITLE OF PRESENTATION TONY KINGSLEY, EXECUTIVE VICE PRESIDENT, GLOBAL COMMERCIAL OPERATIONS

COMMERCIAL UPDATE

Global AVONEX Performance

401464 462 467 491

261

298 274 286 255

662

762 736 753 746

Q1-12 Q2-12 Q3-12 Q4-12 Q1-13

US ROW

11

AVONEX Revenues ($M) Q1 2013 Highlights

Revenue vs. Q1 2012 and Q4 2012 WW* +13% and -1% US +23% and +5% ROW* -2% and -11%

Units vs. Q1 2012 and Q4 2012 WW +4% and -4% US +8% and +0% ROW +1% and -7%

AVONEX Pen is commercially available in 27 countries

Continued to gain market share during the first quarter in the ABCRE segment

11

Note: Numbers may not foot due to rounding

*Net of hedge

Global TYSABRI Performance

201 211 230 243 257

198 184 173190

199

399 395 404433

456

Q1-12 Q2-12 Q3-12 Q4-12 Q1-13

US ROW

12

TYSABRI In-Market Sales ($M) Q1 2013 Highlights In-Market Revenue vs. Q1 2012 and Q4 2012 WW +15% and +5% US +28% and +6% ROW +0% and +5%

BIIB Revenue vs. Q1 2012 and Q4 2012 WW* +9% and +6% US +30% and +9% ROW* +0% and +4%

Units vs. Q1 2012 and Q4 2012 WW +12% and +4% US +22% and +5% ROW +5% and +3%

Approximately 73,600 patients were on commercial and clinical TYSABRI therapy worldwide at the end of the first quarter

ROW Q1 2013 revenues were impacted by $14 MILLION of deferred revenue in our Italian affiliate

12


*Net of hedge

13

1,2007,800

17,00023,800

29,10034,100 35,300 36,300 37,400 38,200 38,600

4,000

12,900

20,100

24,500

27,600

30,00030,800

31,90032,900 33,400 33,900

5,200

21,400

48,900

69,00071,100

72,500 73,600

57,300

37,700

66,80064,700

YE06 YE07 YE08 YE09 YE10 YE11 Q1-12 Q2-12 Q3-12 Q4-12 Q1-13

Int'l Comm'l US Comm'l Clinical Trials

TYSABRI Patient Utilization and Exposure

26,600

33,600

41,100

49,200

59,100

70,100

83,000

TYSABRI Utilization TYSABRI Post-Marketing Exposure

Note: Post-marketing exposure data includes patients exposed since November 23, 2004 and excludes approximately 5,100 patients exposed in clinical trials. Of the clinical trial patients: 2,200 were exposed for >12 months; 1,900 were exposed for >18 months; 1,700 were exposed >24 months; 1,300 were exposed >30 months; 1,000 were exposed >36 months; 700 were exposed >42 months and 700 were exposed >48 months.

Note: Amounts set forth above are rounded and estimated based on information provided to Biogen Idec through the TOUCH® prescribing program and other third-party sources. Such information includes estimates that are based on reasonably available data, but are subject to change. We undertake no obligation to update the amounts set forth above.

Overall Post-marketing

Exposure

>12 Months

>18 Months

>24 Months

>30 Months

>36 Months

>42 Months

>48 Months

13

115,400 NOTE: WE WILL NO LONGER REPORT

PATIENT NUMBERS BEGINNING Q2 2013

14

Progress on TECFIDERATM US Launch Objectives

Sales force trained

Field force engaged with physicians

Physician education training program completed

Educate and Promote to Physicians

TECFIDERA ready for distribution to patients

Comprehensive financial assistance program underway

Payer discussions underway

Facilitate Access to Patients

TITLE OF PRESENTATION R&D UPDATE DOUG WILLIAMS, Ph.D., EXECUTIVE VICE PRESIDENT, RESEARCH & DEVELOPMENT

Multiple Sclerosis (Ph. 1) Optic Neuritis (Ph. 2)

Lupus Nephritis

Idiopathic Pulmonary Fibrosis

General Lupus

Spinal Muscular Atrophy

Neuropathic Pain

Alzheimer's Disease

Pipeline

PHASE I PHASE II PHASE III FILED

16

Multiple Sclerosis

Daclizumab

Multiple Sclerosis TECFIDERA

Hemophilia A

rFIXFc rFVIIIFc

Hemophilia B

PLEGRIDY

Multiple Sclerosis

Chronic Lymphocytic Leukemia & Non-Hodgkin’s Lymphoma Obinutuzumab (GA101)

Secondary Progressive Multiple Sclerosis TYSABRI

Neublastin

Anti-TWEAK

Anti-LINGO

Anti-CD40 Ligand

STX-100

ISIS-SMNRx

BIIB037

*Under Active Review with EMA

FDA APPROVED*

FDA FILED

FDA FILED

Strong TECFIDERA US Label

17

Warnings and Monitoring Low treatment burden with limited monitoring

The most common adverse reactions seen in clinical studies were flushing and gastrointestinal events

A complete blood count is recommended to monitor Lymphopenia before starting treatment, annually, and as clinically indicated

No contraindications

Pregnancy Category C

Indication & Usage Label has broad patient appeal

First-line oral treatment for people with relapsing forms of multiple sclerosis

120 mg twice daily orally for the first 7 days, followed by 240 mg twice daily

Proven to reduce important measures of disease activity, including relapses and the progression of physical disability

2013: Significant Medical Meeting Presence

18

65th American Academy of Neurology Annual Meeting

More than 50 company-sponsored platform and poster presentations presented

Biogen Idec’s MS franchise strengthened with new data for novel treatment options

Data presented demonstrates Biogen Idec’s robust neurology research and development programs

Affirms the company’s decades-long leadership in multiple sclerosis

The 7th Annual Congress of the European Association for

Haemophilia and Allied Disorders Presented data from the Phase III trials of our rFVIIIFc and rFIXFc programs

The data from both studies indicate a potential transformation of the treatment of hemophilia A and B

Potential first long-lasting treatment for hemophilia A and B

BIIB037: Anti-Aβ antibody for Alzheimer's Disease

19

In Vivo Comparison of beta-amyloid (Aβ) Binding

Preferential preclinical binding to insoluble (fibrillar) forms of human Aβ, rather than soluble; more selective for parenchymal amyloid plaques versus vascular deposits compared to similar antibodies in development

Treatment reduces amyloid load in dose dependent manner in mouse AD model

Acceptable safety and tolerability in mild to moderate AD patients at single doses up to 30 mg/kg IV

No incidences of amyloid-related imaging abnormalities of hemorrhage and/or edema in doses up to 30 mg/kg.

mAb Anti-Aβ Development

Candidates

Aβ Binding

Specificity Fibrillar (EC50)

Soluble (EC50)

ch12F6A (BIIB037 analog)

Fibrillar 0.2 nM >1000nM

mGt (Gantenerumab analog)

Fibrillar 0.3nM >1000nM

3D6 (Bapineuzumab analog)

All forms 0.2nM 3nM

m266 (Solanezumab analog)

Soluble 17nM 2nM

Source: Bussière T. et al; 11th International Conference on Alzheimer’s and Parkinson’s Diseases

Phase I study data:

Late Stage Pipeline Events

PROGRAM PHASE INDICATION EXPECTED MILESTONE

TECFIDERA (Dimethyl Fumarate)

Filed in EU Approved in US RRMS

Positive CHMP opinion Under Active Review with European Commission

Long-Lasting Recombinant Factor IXFc Filed in US Hemophilia B BLA submission accepted by FDA;

standard review

Long-Lasting Recombinant Factor VIIIFc Filed in US Hemophilia A Under Active Review with FDA

PLEGRIDY (Peginterferon beta-1a) Phase III RRMS File with FDA & EMA by mid-2013

Daclizumab-HYP Phase III RRMS Data readout 2014

TYSABRI Phase III SPMS Data readout 2015

20

TITLE OF PRESENTATION PAUL CLANCY, EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER

FINANCIAL PERFORMANCE

Q1 2013 GAAP to Non-GAAP Reconciliation

Q1 2013 GAAP Diluted EPS $1.79 GAAP Net Income Attributable to Biogen Idec Inc. ($M) $426.7

Amortization of Intangibles 48.6

Contingent Consideration 2.3

Stock Option Expense 3.5

Tax Impact (11.7)

Total Adjustments 42.7

Non-GAAP Net Income Attributable to Biogen Idec Inc. $469.4 Non-GAAP Diluted EPS $1.97

22 *A RECONCILIATION OF OUR GAAP TO NON-GAAP RESULTS IS INCLUDED AT THE END OF THIS PRESENTATION

Q1 2013 Financial Results Summary

Note: Numbers may not foot due to rounding. Percent changes represented as favorable & (unfavorable).

*Net of Hedge

**US Profit Share = US Profit Share + Expense Reimbursement

23

($) Millions Q1

2012 Q4

2012 Q1

2013 %∆ Q/Q

%∆ Y/Y

AVONEX US $401 $467 $491 5% 23%

AVONEX Int’l* $261 $286 $255 -11% -2%

Total AVONEX Sales* $662 $753 $746 -1% 13%

TYSABRI US $87 $104 $113 9% 30%

TYSABRI Int’l* $198 $191 $199 4% 0%

TYSABRI Rev to BIIB* $286 $295 $312 6% 9%

Other Product Sales $28 $26 $38 46% 36%

Total Product Sales $975 $1,075 $1,096 2% 12%

RITUXAN US Profit Share** $258 $257 $282 10% 9%

RITUXAN ex-US Revenues $27 $24 $(17) NMF NMF

Tot. Rev. from Unconsol. Joint Bus. (RITUXAN) $285 $281 $265 -6% -7%

Corporate Partner Revenues $3 $6 $22 NMF NMF

Royalty $29 $56 $33 -42% 14%

Total Revenue $1,292 $1,418 $1,415 0% 10%

RITUXAN Performance

27 25 29 24 (17)

258 259 259 257 282 285 285 288 281

265

792 784 787 769

865

Q1-12 Q2-12 Q3-12 Q4-12 Q1-13

ROW Royalty BIIB US Profit Share* BIIB Revenue US Net Sales

24

RITUXAN Results ($M) Q1 2013 Highlights

Revenue vs. Q1 2012 and Q4 2012 US Net Sales +9% and +12% US Profit Share* +9% and +10% ROW Royalty NMF and NMF BIIB Revenue -7% and -6%

Revenues driven by continued uptake in first line maintenance in follicular lymphoma

Q1 2013 results include $42M for arbitration charge $4M impacted US profit share $38M impacted ROW Royalties

Note: In collaboration with Roche and Genentech. *US Profit Share = US Profit Share + Expense Reimbursement 24


Q1 2012 Q4 2012 Q1 2013 %∆ Q/Q

%∆ Y/Y

Cost of Sales1 $133 $134 $134 0% 0%

% of Total Revenues 10% 9% 9%

Non-GAAP R&D Expenses2 $354 $344 $283 18% 20%


Non-GAAP SG&A Expenses3 $300 $375 $351 6% -17%


Collaboration Profit Sharing1 (TYSABRI) $86 $78 $85 -10% 1%

Gain on Sale of Rights (BENLYSTA)

N/A $15 $5 NMF NMF


1. For Q1‘12, Q4‘12, Q1’13 there were no adjustments between GAAP and non-GAAP cost of sales or collaboration profit sharing.

2. For Q1‘12 GAAP R&D expense was $356 million and 28% of Total Revenues, non-GAAP R&D expense excludes $1 million in stock option expense. For Q4‘12 GAAP R&D expense was $345 million and 24% of Total Revenues, non-GAAP R&D expense excludes $1 million in stock option expense. For Q1‘13 GAAP R&D expense was $284 million and 20% of Total Revenues, non-GAAP R&D expense excludes $1 million in stock option expense.

3. For Q1’12 GAAP SG&A expense was $300 million and 23% of Total Revenues, non-GAAP SG&A expense excludes less than $1M in stock option expense. For Q4’12 GAAP SG&A expense was $300 million and 22% of Total Revenues, non-GAAP SG&A expense excludes less than $2 million in stock option expense. For Q1'13 GAAP SG&A expense was $352 million and 25% of Total Revenues, non-GAAP SG&A expense excludes $1 million in stock option expense.

25

($) Millions


($) Millions except shares and EPS

Q1 2012

Q4 2012

Q1 2013

%∆ Q/Q

%∆ Y/Y

Other income (expense), net1 $14 $(14) $(14) -1% NMF

Non-GAAP Tax Rate2 22% 31% 14%

Equity in Loss of Investee, net of tax* - $3 $4 NMF NMF

Non-GAAP Net Income attributable to Biogen Idec3 $338 $335 $469 40% 39%

Weighted average diluted shares used in calculating diluted EPS (millions) 242 238 238 0% 1%

Non-GAAP EPS3 $1.40 $1.40 $1.97 41% 41%


1. For Q1'12, Q4'12, Q1’13 other income (expense), net there were no adjustments between GAAP and non-GAAP.

2. For Q1'12 GAAP tax rate was 21%. For Q4'12 GAAP tax rate was 32%. For Q1‘13 GAAP tax rate was 13%. The difference between the GAAP and non-GAAP tax

rate for all periods is a result of the cumulative effects of the reconciliation that can be found on Table 3 from Biogen Idec’s Q1’13 earnings press release or the end of this presentation and the footnotes to the prior slide of this presentation.

3. GAAP diluted EPS was $1.25, $1.23, $1.79 in Q1’12, Q4'12, Q1’13 respectively. GAAP net income attributable to Biogen Idec Inc. was $303 million, $292 million, $427 million in Q1’12, Q4'12, Q1’13 respectively. See Table 3 from Biogen Idec's Q1‘13 press release or the end of this presentation for the most directly comparable GAAP net income attributable to Biogen Idec Inc. and diluted GAAP EPS, with a reconciliation to the non-GAAP net income attributable to Biogen Idec Inc. and diluted non-GAAP EPS.

26 *Represents our share of the results of operations related to our investment in Samsung Bioepis


2013 Full Year Financial Guidance Old

FY 2013 Guidance

New FY 2013

Guidance Comments

Revenues Approximately 10% growth

Approximately 16-18%

Revenue assumptions on core business remain unchanged. Included in this guidance is an additional $425 to 475 million from the TYSABRI asset purchase

Cost of Sales 8% to 10% of revenues

13% to 15% Includes TYSABRI contingent payments and 100% of 3rd party TYSABRI royalties

R&D Expense 22% to 23% of revenues

22% to 23% Now includes an additional $75 million earmarked for business development deals

SG&A Expense 24% to 26% of revenues

24% to 26% No Change

Tax Rate 24% to 26% 22% to 23% For the balance of the year, our effective tax rate is expected to be between 24% and 25%.

GAAP EPS Expected between $6.45 & $6.55

Expected between $6.69 & $6.79

Increase due to TYSABRI asset purchase, Q1 2013 discrete tax benefits, Q1 2013 core business strength offset by $75 million earmarked for business development deals

Non-GAAP EPS Expected between

$7.15 & $7.25 Expected between

$7.80 & $7.90

Increase due to TYSABRI asset purchase, Q1 2013 discrete tax benefits, Q1 2013 core business strength offset by $75 million earmarked for business development deals

Capital Expenditures $250 to $270 million $250 to $270 million No Change

27

Expense ratios apply to both GAAP and Non-GAAP 2013 Full Year Guidance.

27 *A RECONCILIATION OF OUR GAAP TO NON-GAAP RESULTS IS INCLUDED AT THE END OF THIS PRESENTATION

Increased 2013 Full Year Financial Guidance

28 28

GAAP EPS Non-GAAP EPS

Old FY 2013 Guidance Expected between $6.45 & $6.55


A. TYSABRI Asset Purchase Impact $0.15 $0.55

B. Q1 2013 Discrete Tax Benefits $0.16 $0.17

C. Core Business Impact ~ $0.18 ~ $0.18

D. $75M Earmarked for Business Development ~ $(0.25) ~ $(0.25)

New FY 2013 Guidance Expected between $6.69 & $6.79


*A RECONCILIATION OF OUR GAAP TO NON-GAAP RESULTS IS INCLUDED AT THE END OF THIS PRESENTATION

-- GUIDANCE SUMMARY --

Note: Numbers may not foot due to rounding.

TITLE OF PRESENTATION BIOGEN IDEC GEORGE SCANGOS, Ph.D., CHIEF EXECUTIVE OFFICER

Biogen Idec: A Bright Future

30

Strong near-term growth prospects driven by our core business

Entering into an era of significant long-term growth driven by multiple potential new product launches

Building an innovative pipeline to sustain longer-term value creation

TITLE OF PRESENTATION BIOGEN IDEC QUESTIONS & ANSWERS

TITLE OF PRESENTATION BIOGEN IDEC APPENDIX

Neurology Late Stage Programs

33

Molecule TECFIDERA

Dimethyl Fumarate

TECFIDERA Dimethyl Fumarate

PegInterferon β 1-A

TYSABRI

natalizumab TYSABRI

natalizumab Daclizumab

HYP Daclizumab

HYP Ocrelizumab* Ocrelizumab* Ocrelizumab*

Trial Name DEFINE CONFIRM ADVANCE ASCEND STRATIFY II SELECT DECIDE OPERA I OPERA II ORATORIO

Phase Phase III Phase III Phase III Phase IIIb Phase IV Phase II Phase III Phase III Phase III Phase III

Indication RRMS RRMS RRMS SPMS MS RRMS RRMS RMS RMS PPMS

Administration Oral Oral SC Injection IV/Infusion N/A SC Injection SC Injection IV/Infusion IV/Infusion IV/Infusion

Target Enrollment 1,000 1,200 1,500 850 >8,000 600 1,800 800 800 630

Design

1. 240mg BID

2. 240mg TID

3. Placebo

1. 240 mg BID

2. 240 mg TID

3. Placebo 4. Copaxone

20mg SC once daily

1. Placebo 2. 125 mcg

SC every 2 wks

3. 125 mcg SC every 4 wks

1. Placebo 2. 300 mcg IV

every 4 wks

Blood collection at enrollment and annually thereafter for up to two years

1. Placebo 2. 150 mcg

SC every 4 wks

3. 300 mcg SC every 4 wks

Active comparator trial versus Ifn β 1-A

Active comparator trial vs. Ifn β 1-A (Rebif)

Active comparator trial vs. Ifn β 1-A (Rebif)

Placebo comparator

Primary Endpoint

Proportion relapsing at 2 years

ARR at 2 years

ARR at 1 year Proportion of subjects experiencing confirmed progression of disability as measured by a composite endpoint

Correlation of PML incidence with JCV Ab status

ARR at 52 Weeks

ARR at 2-3 years

ARR at 96 Weeks

ARR at 96 Weeks

Time to sustained disability progression

Status EMA Filed,

FDA approved

EMA Filed, FDA

approved

Expect to file with FDA &

EMA by mid-2013

Data readout expected 2015 Ongoing Data readout

2011

Fully enrolled,

expect data 2014

Enrollment completed 1Q

2013

Enrollment completed 1Q 2013

Enrollment completed 1Q

2013

*Biogen Idec and Genentech, Inc. a member of the Roche Group have agreed that Genentech will have responsibility for the further development of ocrelizumab in multiple sclerosis. Genentech will fund 100% of the costs going forward and will be responsible for development and commercialization.

33

Anti-CD-20 Late Stage Programs

34

Molecule Rituxan

(Rituximab) Obinutuzumab (GA101)

Obinutuzumab (GA101)



Trial Name RATE CLL11 GADOLIN GALLIUM GOYA

Phase Phase IIIb Phase III Phase III Phase III Phase III

Indication Front-line Diffuse Large B-Cell or Follicular NHL

Front-line Chronic Lymphocytic Leukemia

Rituxan-refractory indolent Non Hodgkin’s Lymphoma Front-line indolent NHL Front-line Diffuse Large B-

cell lymphoma (DLBCL)

Administration IV Infusion IV Infusion IV Infusion IV Infusion IV Infusion

Target Enrollment 450 780 360 1,400 1,400

Design Prospective, open label, single arm study

Arm A: GA 101 plus Chlorambucil Arm B: Rituxan plus Chlorambucil Arm C: Chlrambucil alone

Arm A: GA101 plus Bendamustine Arm B: Bendamustine

Arm A: GA 101 plus chemotherapy followed by GA 101 maintenance Arm B: Rituxan plus chemotherapy followed by Rituxan maintenance

Arm A: GA101 plus CHOP Arm B: Rituxan plus CHOP

Primary Endpoint Incidence of Grade 3 or 4

infusion-related adverse events resulting from faster infusion

Progression-free survival Progression-free

survival Progression-free survival

Progression-free survival

Status sBLA approved October 2012

Stage 1a (ARM A vs. C) positive

Stage 1b (ARM B vs. C) futility analysis met

Data presentation expected at ASCO 2013

Filing expected in 2013

FPI Q2 2010 Expect data 2015

FPI Q3 2011

FPI Q3 2011 Data readout 2015

34

Hemophilia Late Stage Programs

Molecule Long-Lasting

Recombinant Factor IX Fc (rFIXFc)

Long-Lasting Recombinant Factor VIII Fc

(rFVIIIFc)

Long-Lasting Recombinant Factor IX Fc

(rFIXFc)

Long-Lasting Recombinant Factor VIII Fc

(rFVIIIFc)

Trial Name B-LONG A-LONG KIDS B-LONG KIDS A-LONG

Phase Phase III Phase III Phase III Phase III

Indication Hemophilia B Hemophilia A Hemophilia B Hemophilia A

Administration IV Injection IV Injection IV Injection IV Injection

Target Enrollment 123 ~150 ~20 ~50

Design

1. Weekly Prophylaxis 2. Individualized Interval

Prophylaxis 3. Episodic Treatment 4. Perioperative

Management

1. Individualized Prophylaxis

2. Weekly Prophylaxis 3. Episodic Treatment

1. Prophylaxis Regimen 1. Prophylaxis Regimen

Key Endpoints

• Incidence of Inhibitor Development

• Annualized Bleeding Rate • Response to Treatment







Status Filed with the FDA 4Q 2012

Filed with the FDA 1Q 2013

Actively recruiting Actively recruiting

35 35

Q1 2013 Impact of Foreign Exchange

Q1 2013 FX / Hedge Impact Favorable / (Unfavorable)

Total Revenue $1,415 $(6)* (0)%

R&D Expenses $283 $1 0%

SG&A Expenses $351 $0 0%

Collaboration Profit Sharing $85 $0 0%

36

COMPARED WITH THE SAME QUARTER OF LAST YEAR

*Total revenue excluding the $4 million loss from hedging was lower by $2 million in the quarter versus a year ago due to foreign exchange rates. Numbers may not foot due to rounding.

36

Note: Amounts are in ($) Millions, except percentages. Expenses above are non-GAAP.

GAAP to Non-GAAP Reconciliation

37

Use of Non-GAAP Financial Measures We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered “non-GAAP” financial measures under applicable SEC rules. We believe that the disclosure of these non-GAAP financial measures provides additional insight into the ongoing economics of our business and reflects how we manage our business internally, set operational goals and forms the basis of our management incentive programs. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be viewed in isolation or as a substitute for reported, or GAAP, net income attributable to Biogen Idec Inc. and diluted earnings per share. Our “Non-GAAP net income attributable to Biogen Idec Inc.” and “Non-GAAP earnings per share - Diluted” financial measures exclude the following items from GAAP net income attributable to Biogen Idec Inc. and diluted earnings per share: 1. Purchase accounting and merger-related adjustments. We exclude certain charges related to the 2003 merger between Biogen Inc. and Idec Pharmaceuticals, Inc., certain acquisition-related items, and certain amounts in relation to the consolidation of variable interest entities for which we are the primary beneficiary. These adjustments include charges for in-process research and development, the amortization of certain acquired intangible assets and adjustments to the fair value of our contingent consideration obligations. The exclusion of these charges provides management and investors with a supplemental measure of performance which the Company believes better reflects the underlying economics of the business. 2. Stock option expense recorded in accordance with the accounting standard for share-based payments. We believe that excluding the impact of expensing stock options better reflects the recurring economic characteristics of our business. 3. Other items. We evaluate other items on an individual basis, and consider both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to our ongoing business operations, and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. We also include an adjustment to reflect the related tax effect of all reconciling items within our reconciliation of our GAAP to Non-GAAP net income attributable to Biogen Idec Inc. Numbers may not foot due to rounding.

37

*

EARNINGS PER SHAREMarch 31,

2013December 31,

2012March 31,

2012

GAAP earnings per share - Diluted 1.79$ 1.23$ 1.25$ Adjustments to net income attributable to Biogen Idec Inc. (as detailed below) 0.18 0.17 0.15 Non-GAAP earnings per share - Diluted 1.97$ 1.40$ 1.40$

GAAP net income attributable to Biogen Idec Inc. 426.7$ 292.1$ 302.7$ Adjustments:

Amortization of acquired intangible assets 48.6 49.1 43.3 Fair value adjustment of contingent consideration 2.3 3.6 1.3 SG&A: Stock option expense 1.9 1.3 0.4 R&D: Stock option expense 1.6 0.8 1.0 R&D: Restructuring and other - - 1.3 2010 Restructuring initiatives - - 0.3 Non-controlling interests - - (0.3) Income tax effect related to reconciling items (11.7) (12.3) (11.6)

Non-GAAP net income attributable to Biogen Idec Inc. 469.4$ 334.6$ 338.4$

2013 Full Year Guidance GAAP to non-GAAP adjustments

$ Shares Diluted EPSProjected GAAP net income attributable to Biogen Idec Inc. 1,608$ 239 6.74$

Adjustments:Stock option expense 8 Restructuring and other - Amortization of acquired intangible assets 314 Fair value adjustment of contingent consideration 16 Income tax expense: Income tax effect related to reconciling items (74)

Projected Non-GAAP net income attributable to Biogen Idec Inc. 1,872$ 239 7.85$

An itemized reconciliation between projected EPS on a GAAP basis and on a non-GAAP basis is as follows:

(unaudited, in millions, except per share amounts)

An itemized reconciliation between net income attributable to Biogen Idec Inc. on a GAAP basis and net income attributable to Biogen Idec Inc. on a non-GAAP basis is as follows:

Biogen Idec Inc. and SubsidiariesGAAP to Non-GAAP Reconciliation: Net Income and Net Income Per Share

For the Three Months

BIOGEN IDEC TITLE OF Q1 2013 FINANCIAL RESULTS & BUSINESS UPDATE

Documents

Transcript of BIOGEN IDEC TITLE OF Q1 2013 FINANCIAL RESULTS & BUSINESS UPDATE